Overzicht longkankerstudies in Nederland
Op deze pagina vindt u de lopende longkankerstudies van de aangesloten centra. Maak gebruik van de zoek- en filterfunctie om eenvoudig door het aanbod van de lopende longkankerstudies te navigeren.
A Multicenter, Open-Label Phase 1 Study of Patritumab-Deruxtecan (U3-1402) in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer.
Antoni van Leeuwenhoek
Fase 1 studie naar biologische beschikbaarheid van U3-1042 CTM-3. Daarnaast beoordeling veiligheid en verdraagzaamheid.
A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors.
Antoni van Leeuwenhoek
Fase 1 studie naar de veiligheid en verdraagzaamheid van SGN-PDL1V. Dose and schedule optimization and dose expansion.
A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as monotherapy in adults with advanced solid tumors.
Antoni van Leeuwenhoek
Fase 1 / 2 studie naar veiligheid en verdraagzaamheid van SAR445877 en bepalen van maximaal getolereerde dosis van en aanbevolen dosis. Dosisescalatie en dosis expansie cohort.
A Phase I Study of Zenocutuzumab (MCLA-128), a Human IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumours (eNRGy trial).
Antoni van Leeuwenhoek
Fase I/II studie naar veiligheid, tolerabiliteit, pharmacokinetiek, immunogeniciteit en anti-tumor activiteit van MCLA-128.
A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sabestomig (AZD7789), an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Participants with Advanced or Metastatic Solid Tumors.
Antoni van Leeuwenhoek
Een fase I/IIa open-label dosisverhoging en dosisuitbreidingsstudie om de veiligheid, farmacokinetiek, farmacodynamiek en werkzaamheid van AZD7789, een bi-specifiek antilichaam tegen PD-1 en TIM-3, te onderzoeken bij proefpersonen met gevorderde of gemetastaseerde niet kleincellig longkanker.
A clinical trial of Pembrolizumab (MK-3475) evaluating predictive biomarkers in subjects with advanced solid tumors (KEYNOTE 158).
Antoni van Leeuwenhoek
Evaluatie van voorspellende biomarkers (TMB-H) naar de respons op behandeling met Pembrolizumab.
A phase 1/2 first-in-human study of the safety and efficacy of IMC-F106C as a single agent and in combination with checkpoint inhibitors in HLA-A*02:01-positive participants with advanced PRAME-positive cancers.
Antoni van Leeuwenhoek
Fase 1-2 dosisescalatie studie naar monotherapie IMC-F106C of combinatietherapie met checkpoint inhibitor of chemotherapie.
A phase 1/2 study of BMS-986449 with and without Nivolumab in participants with solid tumors.
Antoni van Leeuwenhoek
Fase 1 dosisescalatie studie naar combinatie van BMS-986449 en nivolumab bij gemetastaseerd NSCLC.
ALKOVE-1
Antoni van Leeuwenhoek
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
AMG355 – a phase 1 first-in-human study evaluating the safety, tolerability, pharmacokinetics and efficacy of AMG355 as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors
Radboud UMC
Non-randomized, open-label.
ARROS-1
Antoni van Leeuwenhoek and UMC Groningen
a FIH, Phase 1/2, multicenter, open-label, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520
AirWaze - Easy and Advanced Tools for CBCT Guided Lung Interventions
Radboud UMC
Primary Purpose: Diagnostic, Interventional Model: Single Group Assignment, Masking: None (Open Label)
BAY2927088
Antoni van Leeuwenhoek and Erasmus MC
An open label, first-in-human study of BAY2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation.
BO 42777
MUMC+
Study BO42777 is a Phase IIII, global, multicenter, multicohort study to evaluate the efficacy and safety of multiple therapies in patients with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status. This population is based on the Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) NSCLC staging system Patients with tumors harboring a cohort-eligible biomarker identified through one of the methods specified as follows will be screened for enrollment in the applicable cohort of this study
BX43361
MUMC+
Study BX43361 is a global, interventional, multicenter, master biomarker screening study. The overarching structure of this study is a flexible master screening process that will test patients’ tumor tissue to determine biomarker status using a central laboratory. Tumor tissue from eligible patients will be submitted for centralized, indication-appropriate biomarker testing, as needed for linked trials. The results of this testing will be used to identify patients with an appropriate biomarker profile, for potential participation in a linked Roche clinical trial.… This master screening study will be conducted initially only to identify biomarker eligible patients with either locally advanced, unresectable Stage III NSCLC or Stage II, IIIA, or select IIIB (T3N2 only) NSCLC requiring adjuvant treatment (see Appendix 2). However, it is anticipated that Study BX43361 will be amended in the future to include additional linked Roche clinical trials. - No therapeutic intervention will be administered to patients in this screening study.
Basket of Baskets: A modular, open-label, phase II, multicentre study to evaluate targeted agents in molecularly selected populations with advanced solid tumour.
Antoni van Leeuwenhoek
Fase 2 studie waarbij in geselecteerde patiëntenpopulatie (voor longkanker MET mutatie/MET CNG ≥6) amivantamab 2 wekelijks gegeven wordt.
Beamion lung 2
MUMC+
This is a multi-regional, multi-centre, open-label, randomized, active-controlled, parallel-group Phase III trial of orally administered zongertinib (BI 1810631) versus SoC (intravenous pembrolizumab combined with platinum-pemetrexed chemotherapy
CA120-1001
UMC Groningen
CA1201001 is a Phase 1/2, FIH, multi-center, open-label study of oral BMS-986449 administered as a single agent and in combination with nivolumab in participants with advanced solid tumors.
CD137/FAP
Amsterdam UMC
An Open Label, Phase I Dose-finding Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers
CIAG933A12101
Erasmus MC
CIAG933A12101 An open-label, multicenter, Phase I study of oral IAG933 in adult patients with advanced Mesothelioma and other solid tumors.
CLN-081-001 (REZILIENT1)
Antoni van Leeuwenhoek and LUMC
This is a Phase 1/2, open-label, multicenter, first-in-human trial to evaluate the safety and tolerability, PK, PD, and preliminary efficacy of CLN-081 in patients with locally-advanced or metastatic NSCLC harboring EGFR ex20ins mutations who have previously received platinumbased systemic chemotherapy. Module A of this study is an open-label, randomized, 2-treatment arm crossover food effect PK assessment module.
CodeBreak 202 -AMGEN20190341 Phase 3 studie 1L Sotorasib UMCG
UMC Groningen and MUMC+
This is a phase 3, international, multicenter, randomized, open-label study to evaluate the efficacy and safety of sotorasib in combination with carboplatin and pemetrexed versus pembrolizumab in combination with carboplatin and pemetrexed in front-line setting in subjects with Stage IV or advanced Stage IIIB/C nonsquamous PD-L1 negative and KRAS p.G12C-mutation positive NSCLC.
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)
Amsterdam UMC, Antoni van Leeuwenhoek, Erasmus MC, LUMC, MUMC+, Radboud UMC and UMC Groningen
The ADAPT ALEC trial is a phase IV, RCT in patients with ALK positive NSCLC treated with alectinib. A longer median progression free survival (mPFS) is expected in patients treated with standard dose alectinib when minimum plasma concentrations (Cmin) of alectinib exceed 435 ng/mL.
DIRECT
Amsterdam UMC, DIJKLANDER and OLVG
A single medium-dose radiotherapy, followed by a single dose Durvalumab and surgery for tumor microenvironment modification in early stage NSCLC
DO-2
Erasmus MC and Radboud UMC
fase 1-studie om de veiligheid en farmacokinetiek van de selectieve MET-kinaseremmer DO-2 te bepalen bij patiënten met gevorderde of refractaire solide tumoren
DeLLphi-305
Erasmus MC
DeLLphi-305 A phase 3, open-label, multicenter, randomized study of Tarlatamab in combination with Durvalumab vs Durvalumab alone in subjects with extensive-stage small-cell lung cancer following Platinum, Etoposide and durvalumab.
Dedication-1 – NVALT 30
Radboud UMC, MUMC+, Erasmus MC and UMC Groningen
An open label non-inferiority trial of reduced dose pembrolizumab versus standard of care dose pembrolizumab NSCLC patients who are eligible for treatment with a pembrolizumab-based regimen.
Destiny Lung 04 (D967SC00001)
UMC Groningen, Radboud UMC and Amsterdam UMC
This is a Phase 3, randomized, open-label, 2-arm, multicenter, international study assessing the efficacy and safety of T-DXd compared with SoC (platinum-based chemotherapy with pemetrexed in combination with pembrolizumab) in participants with NSCLC harboring HER2 mutations in exon 19 or 20
Dose tapering and early discontinuation to increase cost-effectiveness of immunotherapy trial number 1
Erasmus MC
An open label randomized non-inferiority study.
Drug Access Protocol (DAP)
Amsterdam UMC, Antoni van Leeuwenhoek, Erasmus MC, UMC Groningen, MUMC+ and Radboud UMC
A Dutch National Protocol to Facilitate Patient Access to Novel Anti-cancer Drugs Awaiting Regulatory Approval or Reimbursement (for met selpercatinib, capmatinib, larotrectinib, entrectinib or tepotinib)
Drug Rediscovery Protocol (DRUP)
Amsterdam UMC, Erasmus MC, UMC Groningen, MUMC+ and Radboud UMC
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile
ELDAPT
MUMC+
Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy
ENSURE
Erasmus MC
Phase I, Open-Label Study With Dendritic Cell therapy (MesoPher) In Combination With Extended-Pleurectomy/Decortication After Chemotherapy in Subjects With Resectable Mesothelioma ENSURE (dENdritic cell therapy combined with SURgEry in mesothelioma)
ETOP-CHESS cohort 2
MUMC+
Single arm, multicentre phase II trial evaluating the efficacy in terms of 1-year PFS rate of immunotherapy and chemotherapy plus stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the locoregional primary tumour in patients with oligo-metastatic NSCLC.
FURMO-004
Antoni van Leeuwenhoek
Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib at 2 dose levels (160 mg and 240 mg) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic nonsquamous NSCLC with EGFR exon 20 insertion mutations.
Fortitude-301 – a phase 1b/2, multicenter, open-label basket study evaluating the safety and efficacy of Bemarituzumab monotherapy in solid tumors with FGFR2b overexpression
Radboud UMC
Non-randomized, open-label
GO41596
Amsterdam UMC
A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
INCLUSION ON HOLD: AMG757 (Amg20200469, DeLLphi-303) Tarlatamab
UMC Groningen
Open Label fase II
INCLUSION ON HOLD: BI1438-0004: An open-label Phase I PET imaging trial to investigate [89Zr]Zr-BI 764532 biodistribution and tumour uptake in patients with small-cell lung carcinoma or neuroendocrine carcinoma
Amsterdam UMC
Phase I, open-label interventional biodistribution trial
INCLUSION ON HOLD: PAULIEN
Amsterdam UMC
Pembrolizumab alone versus pembrolizumab-chemotherapy in first line NSCLC
INCLUSION ON HOLD: RAMP VS-6766-203
Erasmus MC and LUMC
INCLUSION ON HOLD: RAMP VS-6766-203 A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer
INCLUSION ON HOLD: TNO155
Erasmus MC
open-label, multi-center, fase I, dose finding studie met oraal TNO155 in volwassen patienten met gemetastaseerd NSCLC met KRAS G12C mutatie (expansie fase)
ION BIOPSY
Radboud UMC
A prospective, dual-arm, interventional study. Prospective collection of consecutive patients undergoing a biopsy procedure with the Ion Endoluminal system with CBCT imaging, and comparing these results with the prospectively collected cohort of CBCT-navigation bronchoscopy procedures performed at Radboudumc.
IPON-1
MUMC+
Immune profiling of stage III non-small cell lung cancer patients treated with concurrent chemoradiation and adjuvant durvalumab: A prospective observational phase II trial
KRASCENDO
Radboud UMC
A phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of divarasib in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation (BO44426)
Libretto-432 J2G-MC-JZXZ
Radboud UMC
Study J2G-MC-JZJX (JZJX) is a randomized, double-blind, Phase 3 study comparing the efficacy and safety of selpercatinib twice daily (BID) to placebo in participants with RET fusion-positive Stage IB-IIIA NSCLC following completion of therapies with a curative intent.
M18-868
MUMC+
Phase 3 Open-Label, Randomized, Controlled, Global Study in Subjects with Previously Treated c-Met+, EGFR Wildtype, Locally Advanced/Metastatic Nsclc ; with Previously Treated c-Met+, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous
M24VUD
Antoni van Leeuwenhoek
Fase 1b/2 studie naar vudalimab in combinatie met chemotherapie of pembrolizumab in combinatie met chemotherapie als eerstelijnsbehandeling bij NSCLC
MEDI4736
Erasmus MC
International, randomized phase III trial. Patients will be randomized 1:1 stratified for established prognostic factors (presence of brain metastases, and presence of liver metastases) to receive chemoimmunotherapy plus TRT or chemoimmunotherapy alone.
MEDI5752
Erasmus MC and Antoni van Leeuwenhoek
This is a randomized (1:1), open-label, Phase III trial in participants with untreated unresectable PM evaluating volrustomig (MEDI5752) in combination with carboplatin and pemetrexed compared to investigator’s choice of nivolumab and ipilimumab or platinum plus pemetrexed chemotherapy for participants with epithelioid histology, and nivolumab plus ipilimumab for participants with non-epithelioid histology.
MK-2870
Erasmus MC
This is a randomized, active-controlled, parallel-group, multisite, open-label study of adjuvant pembrolizumab with or without MK-2870 in participants with resectable Stage II to IIIB (N2) NSCLC who did not achieve pCR after receiving neoadjuvant pembrolizumab with platinum-based doublet chemotherapy followed by surgery.
ML41176-BIO
Antoni van Leeuwenhoek, UMC Groningen, MUMC+ and Radboud UMC
Unraveling tumor response and resistance to combined chemotherapy and PD-L1 inhibition with minimal invasive techniques in patients with advanced NSCLC with targetable disease
MO41552
Antoni van Leeuwenhoek, Erasmus MC and Radboud UMC
MO41552 Randomized, Open label, Multicenter, Phase III study of Entrectinib versus Crizotinib in patients with locally advanced or metastatic Non-Small Cell Lung Cancer harboring ROS1 gene rearrarangements with and without central nervous system metastases.
MOMENT
LUMC
Prospectieve multi-nationale ziekte registratie studie
NEOpredict
Antoni van Leeuwenhoek
This is an international, multicenter, open-label, randomized, three-armed, modular phase II study. Patients with histologically confirmed non-small cell lung cancer (NSCLC) of clinical stages I B, II and selected stage III A (T3 N1, T4 with satellite nodule in the same lung N0/N1, selected T1a-T2b N2 cases considered suitable for primary surgical approach by the multidisciplinary tumor board), who are eligible for anatomic resection will be included. Subjects in all arms will receive 2 preoperative treatment cycles with a cycle duration of 14 days. Study treatment consists of nivolumab q2w in Arm A, and nivolumab q2w plus relatlimab q2w in Arms B and C.
OSIBOOST 2
Antoni van Leeuwenhoek, Erasmus MC, MUMC+ and UMC Groningen
Using Cobicistat as a pharmacokinetic booster of Osimertinib and implementing alternative dose-regimens to improve cost-effectiveness of advanced Non-Small Cell Lung Cancer treatment OSIBOOST 2-A and OSIBOOST 2-B.
PRT3789-01
LUMC
Open-label, multi-center, first-in-human fase 1 dosis escalatie studie
Prediction
LUMC
Prospectief observationeel multicenter studie
RAMP 203 Verastum
LUMC
Fase 1/ 2 dosis evaluatie en expansie studie
SATIN
Amsterdam UMC, Erasmus MC, MUMC+ and Radboud UMC
Safety of TKI concurrent with cranial radiotherapy in NSCLC patients; the SATIN platform trial
SGNB6A-002
Erasmus MC and MUMC+
A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer
SHARP: A clinical imaging Study of the changes in [18F]F-AraG uptake following Radiotherapy in Non-small cell lung cancer.
Amsterdam UMC
A clinical imaging Study of the changes in [18F]F-AraG uptake following anti-PD-1 therapy in Non-small cell lung cancer
SIRP-α
Amsterdam UMC
An open label Phase I PET imaging study to investigate the biodistribution and tumor uptake of [89Zr]Zr-BI 765063 in patients with head and neck squamous cell carcinoma, non-small cell lung cancer or melanoma who are also treated with ezabenlimab
Safety and efficacy of a flexible endobronchial sampling instrument that obtains a CORe sample from KeY suspected areas of pulmonary and mediastinal lesions. - COReKeY
Radboud UMC
Open (masking not used), Uncontrolled, Parallel, Diagnostic
TAS6417-301
Amsterdam UMC, Radboud UMC and Antonie van Leeuwenhoek
Randomized, Controlled, Open-label, Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations. (REZILIENT3)
TBPETCT001
Amsterdam UMC
Exploring new imaging opportunities using a large axial field of view PET-CT system
TIGER Meso
Erasmus MC
Non-interventional, observational, prospective, multicentre study on a marketed medical device used in routine clinical care settings following its Instruction For Use within in the approved population
TIL in NSCLC
LUMC
Fase 1 monocenter single-arm interventie studie
TRIDENT-1
Antoni van Leeuwenhoek and UMC Groningen
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 (Repotrectinib) in Patients With Advanced Solid Tumors Harboring ROS1, or NTRK1-3 Rearrangements
TROPION-LUNG08 / DS1062-AU304
Amsterdam UMC
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations): TROPION-LUNG08
The beneficial value of 18F FDG PET/CT in the follow-up of stage III non-small cell lung cancer patients: the NVALT31-PET study
Amsterdam UMC, Radboud UMC and UMC Utrecht
This is a multicenter randomized controlled clinical trial with a superiority design. At approximately 4 months after the end of curative intent treatment patients will be randomized 1:1 to either the intervention (18F FDG PET/CT) or the control group (usual care, CT-based follow-up). Randomization will be done stratifying for histology and treatment.
Tropion-Lung 07
LUMC
Gerandomiseerde fase 3 studie
Tropion-Lung 08
LUMC
Gerandomiseerde, fase 3 studie
UPLAN-1
MUMC+, UMC Groningen
UPFRONT RESECTION OF LOCALLY ADVANCED NSCLC FOLLOWED BY CHEMORADIOTHERAPY (AND ADJUVANT SYSTEMIC TREATMENT); PHASE I MULTICENTER STUDY TO ASSESS TREATMENT FEASIBILITY AND SAFETY (UPLAN-ITRIAL)
USZ-STRIKE
Antoni van Leeuwenhoek
Prospective phase III, multicentre randomised (1:1) open label superiority study
Validation of Rapid On-site Diagnostics in Early Stage Lung Cancer Sampling With a Higher Harmonic Generation Microscope (VALIDIAG)
Radboud UMC
Observational Model: Case-Only, Time Perspective: Prospective, Target Follow-up Duration: 20 Years
eNRGy
Antoni van Leeuwenhoek
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single indication expansion group assignment study to assess the safety, tolerability, PK, PD, immunogenicity and antitumor activity of MCLA-128. T
eVOLVE-Lung02
Amsterdam UMC
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
iRelate
Amsterdam UMC
Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer